case / 01 Jul 2020

Setterwalls advises Ascelia Pharma in connection with SEK 98.7 million private placement

Responsive image

Ascelia Pharma has conducted a private placement of SEK 98.7 million through a new issue of approximately 4.7 million shares at a price of SEK 21 per share. The new issue was directed at a number of Swedish and international institutional investors. The proceeds will be used to accelerate the pre-commercial activities for the planned launch of the product candidate Mangoral, which is currently in the Phase 3 clinical study SPARKLE, as well as for general corporate purposes. Setterwalls has acted as legal advisor to Ascelia Pharma in connection with the private placement.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Mangoral and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ACE).

Do you want to get in touch with us?

Please fill out the form and we will contact you as soon as possible.

  • This field is for validation purposes and should be left unchanged.